Preliminary outcome of IBS' rights issue IBS' new share issue with preferential rights for the Company's existing shareholders has been completed. The final outcome of the rights issue will be announced on Thursday, July 10. The preliminary outcome is as follows. Deccan Value Advisors, having issued a subscription guarantee, subscribed for its pro rata share of the rights issue and an additional 75,000 class A shares and an additional 11,087,943 class B shares. Accordingly, the rights issue was subscribed for in its entirety. Following completion of the rights issue, Deccan Value Advisors owns 17.1 percent of the shares and 36.9 percent of the votes in IBS. As a consequence of the rights issue, the number of shares in IBS increases by 1,575,000 class A shares and 40,229,015 class B shares. Following the issue, 4,725,000 class A shares and 120,687,045 class B shares will be outstanding. Trading in the new class B shares on OMX Nordic Exchange Stockholm is scheduled to commence on July 17, 2008. The rights issue will provide the company with approximately SEK 397 million before transaction costs. Additional class B shares will be issued shortly as consideration for Deccan Value Advisors subscription guarantee. The exact number of shares issued will be stated in a separate press release as soon as the formal resolution to issue the shares has been adopted. IBS AB Board of Directors For more information, please contact: Oskar Ahlberg, Investor Relations Director, IBS AB Tel : +46-70-244 24 75 oskar.ahlberg@ibs.net IBS (OMX Nordic Exchange STO: IBS) is a leading provider of specialized business systems for specific industries such as publishing and book distribution, pharmaceutical distribution, electrical and electronic parts and equipment, paper, food and the automotive industry. IBS focuses on large and mid-sized companies within supply chain management, demand-driven manufacturing, customer administration and financial control. For further information, visit www.ibs.net
Preliminary outcome of IBS' rights issue
| Source: IBS AB